[HTML] thelancet.comFull View

[HTML][HTML] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

H Adderley, FH Blackhall, CR Lindsay - EBioMedicine, 2019 - thelancet.com
KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …
被引用次数：185 相关文章

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

H Adderley, FH Blackhall, CR Lindsay - EBioMedicine, 2019 - pubmed.ncbi.nlm.nih.gov
KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.

H Adderley, FH Blackhall, CR Lindsay - Ebiomedicine, 2019 - europepmc.org
KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

[引用][C] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

H Adderley, FH Blackhall, CR Lindsay - EBioMedicine, 2019 - cir.nii.ac.jp
KRAS-mutant non-small cell lung cancer: Converging small molecules and immune
checkpoint inhibition | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] …
[HTML] sciencedirect.com

[HTML][HTML] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

H Adderley, FH Blackhall, CR Lindsay - EBioMedicine, 2019 - Elsevier
KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …

KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

H Adderley, FH Blackhall, CR Lindsay - EBioMedicine, 2019 - research.manchester.ac.uk
KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …
[HTML] nih.gov

[HTML][HTML] KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

H Adderley, FH Blackhall, CR Lindsay - EBioMedicine, 2019 - ncbi.nlm.nih.gov
KRAS is the most frequent oncogene in non-small cell lung cancer (NSCLC), a molecular
subset characterized by historical disappointments in targeted treatment approaches such …